



Customer No. 22,852
Attorney Docket No.: 01975.0047

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
)	
Josephus H. M. LANGE et al.)	
)	Group Art Unit: 1614
Serial No.: 10/662,477)	
)	Examiner: Not Yet Assigned
Filed: September 16, 2003)	
)	
For: 1H-1,2,4-TRIAZOLE-3-CARBOXAMIDE)	
DERIVATIVES HAVING CANNABINOID-CB ₁)	
RECEPTOR AGONISTIC, PARTIAL)	
AGONISTIC, INVERSE AGONISTIC OR)	
ANTAGONISTIC ACTIVITY)	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97(b)**

Pursuant to 37 C.F.R. §§1.56 and 1.97(b), Applicants bring to the Examiner's attention the documents listed on the attached Form PTO-1449. Copies of the listed documents are attached. Applicants respectfully request that the Examiner consider the listed documents on the attached Form PTO-1449 and indicate that they were considered by making an appropriate notation on that form. This Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

For the Examiner's convenience, Applicants also enclose a copy of the European Search Report issued during the prosecution of the priority application, EP 02 07 8966.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that any of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents. Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should any of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: April 9, 2004


By: 

Jeremy M. Stipkala
Reg. No. 44,359

684276_1

SUPPLEMENTAL INFORMATION DISCLOSURE CITATION

Atty. Docket No.	01975.0047	Serial No.	10/662,477
Applicants	Josephus H. M. LANGE et al.		
Filing Date	September 16, 2003	Group:	1614



U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
	5,624,941	04/29/97	Barth et al.			
	4,795,484	01/03/89	Aoki et al.			

FOREIGN PATENT DOCUMENTS

Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
WO 01 29007 A1	04/26/01	PCT			
WO 01 58869 A2	08/16/01	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Dyck, et al., "Potent Imidazole and Triazole CB ₁ Receptor Antagonists Related to SR141716," <i>Bioorganic & Medicinal Chemistry Letters</i> , 14:1151-1154 (2004).
	Harhash et al., "Reactions of 2-aryl-4-arylhydrazono-DELTA. 2-oxazolin-5-ones with acid amides and diamines," XP002225874 Abstract, 6001 <i>Chemical Abstracts</i> , 85(23) (1976).
	Elnagdi et al., "Studies with Polyfunctionally Substituted Heteroaromatics: 2-phenyl-4-p-tolyhydrazono-2-oxazoline-5-one as a Precursor for the Synthesis of Substituted 1,2,4-Triazoles and Pyridines," XP-002225875 Abstract, 6001 <i>Chemical Abstracts</i> , 124(17), (1996).
	Jagerovic et al., "A Novel Class of Heterocyclic Cannabinoids: Design, Preparation, in vitro and in vivo Studies of 1,2,4-Triazoles," XP-001121041 Abstract, <i>Drugs Future</i> 27(Suppl. A): XVI th Int. Symp. on Medicinal Chemistry (2002).

Examiner	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce

684264_1